{
  "abstract": "Background: The management of oligometastatic breast cancer (OMBC) remains controversial, particularly regarding selection for local ablative treatment (LAT). In HR+/HER2− OMBC, where prolonged survival is often the case, improved stratification and characterization of progression may guide treatment. We aimed to define prognostic subsets, assess the contribution of Modern-Imaging-Methods (MIMs; 18F-FDG-PET/CT or WB-MRI) to LAT selection, and describe progression after first-line therapy in these subgroups of patients.\n\nMaterials and Methods: All consecutive patients with HR+/HER2− OMBC treated at our institution between 2012 and 2020 were included. OMBC was defined as ≤5 metastases. Prognostic factors, including biological subtype, anatomical distribution, imaging modality, and LAT, were evaluated for overall and progression-free survival (OS, PFS).\n\nResults: Among 145 patients (median follow-up 82.8 months), median OS and PFS were, respectively, 81.1 and 26.5 months. Luminal-A-like subtypes, absence of liver metastases, and use of MIMs independently predicted better survival. LAT improved PFS (hazard ratio [HR] = 0.52; 95% CI: 0.29-0.91, P = .0233) and showed a trend toward longer OS. In patients staged with MIMs, LAT significantly improved both OS (HR = 0.29; 95% CI: 0.12-0.73, P = .008) and PFS (HR = 0.40; 95% CI: 0.21-0.77, P = .0064). After first-line systemic therapy, only 18% developed polymetastatic progression.\n\nConclusion: In HR+/HER2− OMBC, 3 actionable considerations emerge: staging must incorporate modern imaging to accurately define metastatic burden; LAT may be considered in selected patients with low-grade disease, absence of liver metastases, and long disease-free interval; in oligoprogression after first-line therapy, LAT should be re-evaluated within a multidisciplinary setting. These data offer pragmatic benchmarks to individualize treatment while awaiting definitive randomized evidence.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 13,
  "authors": [
    {
      "name": "Jean-Louis Lacaze",
      "orcid": "0000-0002-7889-0213"
    },
    {
      "name": "Bastien Cabarrou",
      "orcid": "0000-0003-1477-6013"
    },
    {
      "name": "Thibaut Cassou-Mounat",
      "orcid": "0000-0002-8395-4373"
    },
    {
      "name": "Ciprian Chira"
    },
    {
      "name": "Celine Dalmasso",
      "orcid": "0000-0003-3231-1447"
    },
    {
      "name": "Eleonora De Maio",
      "orcid": "0000-0003-2749-1535"
    },
    {
      "name": "Eva Jouve",
      "orcid": "0000-0001-5873-286X"
    },
    {
      "name": "Clément Korenbaum",
      "orcid": "0000-0002-9446-0440"
    },
    {
      "name": "Carole Massabeau",
      "orcid": "0000-0002-0818-7346"
    },
    {
      "name": "Vincent Nicolai"
    },
    {
      "name": "François Poumeaud",
      "orcid": "0000-0002-4453-187X"
    },
    {
      "name": "Gabrielle Selmes",
      "orcid": "0000-0001-7666-600X"
    },
    {
      "name": "Mony Ung"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/e5wm4r5efn8mn.bib",
  "cited_by": 0,
  "doi": "10.1093/oncolo/oyag413",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13722509/",
  "id": "e5wm4r5efn8mn",
  "issns": [
    "1083-7159",
    "1549-490X"
  ],
  "landing_url": "https://doi.org/10.1093/oncolo/oyag413",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "AcademicSubjects/MED00010"
    ],
    [
      "heading",
      "Breast Cancer"
    ],
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "1306|Breast Cancer Treatment Studies"
    ]
  ],
  "openalex": "W7223018463",
  "pdf_url": "https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyag413/72125027/oyag413.pdf",
  "pmcid": "PMC13722509",
  "pmid": "42898011",
  "published": "2026-10-19",
  "publisher": "Oxford University Press",
  "ris": "https://research.draconitic.com/paper/e5wm4r5efn8mn.ris",
  "sources": [
    {
      "first_seen": "2026-11-03T12:22:59Z",
      "native_id": "PMC13722509",
      "source": "pmc",
      "url": "https://doi.org/10.1093/oncolo/oyag413"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:1306|Breast Cancer Treatment Studies",
      "subfield": "oncology"
    }
  ],
  "title": "Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression",
  "title_text": "Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression",
  "type": "peer-reviewed",
  "updated_at": "2026-11-03T12:22:59Z",
  "url": "https://research.draconitic.com/paper/e5wm4r5efn8mn",
  "venue": "The Oncologist",
  "versions": []
}